Clinical trials in testicular cancer

Charles F. Kettering Prize, Lawrence H. Einhorn

Research output: Contribution to journalArticle

21 Scopus citations

Abstract

Testicular cancer has become a model for a curable neoplasm. Our studies with cisplatin combination chemotherapy allow us to conclude that (1) short-duration intensive induction therapy with the most active agents in optimal dosage is more important than maintenance therapy; (2) modest dose escalation increases toxicity without improving therapeutic efficacy; (3) it is possible to develop curative salvage therapy for refractory germ cell tumors; and (4) preclinical models predicting synergism, such as vinblastine+bleomycin or cisplatin+VP-16, have clinical relevance. Finally, testicular cancer also has become a model for new drug development. Cisplatin was approved by the FDA for testis and ovarian cancer and VP-16 and ifosfamide for refractory germ cell tumors. The success of these studies confirms the importance of the continued search for new investigational drugs in all solid tumors.

Original languageEnglish (US)
Pages (from-to)3182-3184
Number of pages3
JournalCancer
Volume71
Issue number10
DOIs
StatePublished - May 15 1993

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Clinical trials in testicular cancer'. Together they form a unique fingerprint.

  • Cite this